
Impact Score
Impact Score


| Metrik | Wert | Einheit | Jahr | PDF Name | PDF Seite | |
|---|---|---|---|---|---|---|
CEO-Mitarbeiter:innen-Verhältnis | ||||||
| 1 009 004 | ($) | 2024 | SEC Filing | 4D Molecular Therapeutics.pdf | 30 | ||
| 227 | employees | 2024 | 0001140361-25-016323.pdf | 33 | ||
| 57 383 | dollars in thousands): | 2024 | 0001140361-25-016323.pdf | 108 | ||
| David Kirn | 2024 | 0001140361-25-016323.pdf | 123 | |||
Belästigung und Diskriminierung am Arbeitsplatz | ||||||
| Yes | 2024 | 4DMT - Code of Business Conduct and Ethics (2024).pdf | 2 | |||
| Yes | 2024 | 4DMT - Code of Business Conduct and Ethics (2024).pdf | 10 | |||
| Yes | 2024 | 4DMT - Code of Business Conduct and Ethics (2024).pdf | 2 | |||
| Yes | 2024 | 4DMT - Code of Business Conduct and Ethics (2024).pdf | 3 | |||
Gewerkschaftsbildung und Tarifverhandlungsmacht | ||||||
| 0 | employees | 2024 | 0001140361-25-016323.pdf | 33 | ||
| 227 | employees | 2024 | 0001140361-25-016323.pdf | 33 | ||
Frauen im Vorstand | ||||||
| 7 | members | 2024 | SEC Filing | 4D Molecular Therapeutics.pdf | 19 | ||
| 5 | Name | 2024 | SEC Filing | 4D Molecular Therapeutics.pdf | 28 | ||
| 0 | Name | 2024 | SEC Filing | 4D Molecular Therapeutics.pdf | 28 | ||
| 2 | Name | 2024 | SEC Filing | 4D Molecular Therapeutics.pdf | 11 | ||
